Clinical Trial Detail

NCT ID NCT02142738
Title Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

Therapies

Cisplatin

Paclitaxel

Carboplatin

Gemcitabine

Pembrolizumab

Pemetrexed

Age Groups: adult

Additional content available in CKB BOOST